135 related articles for article (PubMed ID: 25514168)
1. Eruptive nevi and hair depigmentation related to regorafenib.
Sibaud V; Munsch C; Lamant L
Eur J Dermatol; 2015; 25(1):85-6. PubMed ID: 25514168
[No Abstract] [Full Text] [Related]
2. Regorafenib in metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
[No Abstract] [Full Text] [Related]
3. Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer.
Sugita K; Kawakami K; Yokokawa T; Mae Y; Toya W; Hagino A; Suzuki K; Suenaga M; Mizunuma N; Yamaguchi T; Hama T
Anticancer Res; 2015 Jul; 35(7):4059-62. PubMed ID: 26124355
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
Grothey A
Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
[No Abstract] [Full Text] [Related]
5. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
6. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
Draper A
Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
[No Abstract] [Full Text] [Related]
8. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
[TBL] [Abstract][Full Text] [Related]
9. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
Mitchell J; Khoukaz T; McNeal D; Brent L
Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
11. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.
Wong AL; Lim JS; Sinha A; Gopinathan A; Lim R; Tan CS; Soh T; Venkatesh S; Titin C; Sapari NS; Lee SC; Yong WP; Tan DS; Pang B; Wang TT; Zee YK; Soong R; Trnkova Z; Lathia C; Thiery JP; Wilhelm S; Jeffers M; Goh BC
J Transl Med; 2015 Feb; 13():57. PubMed ID: 25889309
[TBL] [Abstract][Full Text] [Related]
12. A closer look at regorafenib.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2018 Oct; 16(10):667-669. PubMed ID: 30543596
[No Abstract] [Full Text] [Related]
13. Bilateral sensorineural hearing loss induced by regorafenib.
Cheng J; Wang L; Zhu LN; Wang L
J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
[TBL] [Abstract][Full Text] [Related]
14. [Investigation of Administration Technique of Regorafenib in Our Center].
Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Motoori M; Nakatsuka R; Nishimura M; Kitagawa A; Takagi M; Iwase K
Gan To Kagaku Ryoho; 2017 Jan; 44(1):47-51. PubMed ID: 28174379
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
16. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
[TBL] [Abstract][Full Text] [Related]
17. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
[TBL] [Abstract][Full Text] [Related]
18. [Stevens-Johnson syndrome induced by regorafenib in a patient with progressive recurrent rectal carcinoma].
Mihara Y; Yamaguchi K; Nakama T; Nakayama G; Kamei H; Ishibashi N; Uchida S; Akagi Y; Ogata Y
Gan To Kagaku Ryoho; 2015 Feb; 42(2):233-6. PubMed ID: 25743146
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
[No Abstract] [Full Text] [Related]
20. Comment on: "Regorafenib: Start Low and Go Slow".
de la Fouchardière C
Target Oncol; 2016 Feb; 11(1):123-5. PubMed ID: 26634250
[No Abstract] [Full Text] [Related]
[Next] [New Search]